Nevertheless, a prospective double-blind study in patients with mild AD failed to demonstrate that a 8 mg Cu daily supplementation produced an effect on tau and phospho-tau levels in cerebrospinal fluid (CSF) that represent relevant markers for AD [16]. This evidence concerns the gene MAPT and Alzheimer disease.